Current and Emerging BTK Inhibitors for Chronic Lymphocytic Leukemia
Researchers sought to determine the landscape of BTK inhibitors for treating patients with CLL.
Researchers sought to determine the landscape of BTK inhibitors for treating patients with CLL.
About 81% of patients had lymphoproliferative malignancies.
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.